Unpacking the Innovation Disconnect

Brands are faced with many challenges in today’s landscape, from tough competition to supply chain interruptions to elevated consumer demands and more. One common theme we hear from our brand partners, no matter their industry, is a focus on innovation. But, despite innovation being a clear differentiator for brands looking maintain success, innovation is often overlooked or underprioritized as businesses work towards growth. This is what we have come to recognize as the “innovation disconnect.” 

Innovation: The Key to Scalability

In a 2023 McKinsey survey of more than 1000 executives, two-thirds stated that their companies current business models would not be economically viable by 2025, and identified innovation as a potential solution. The same survey found that organizations who view innovation as a core value, or those that are ahead of the curve in utilizing technology, are more likely to succeed and outperform against competitors. 

We see this positive sentiment regarding the impacts of innovation echoed throughout market research: 

There are many reasons why innovation is so important to sustained business growth, from ensuring the necessary adaptability to overcome unexpected challenges, to helping brands stand out in an over-saturated marketplace. Data suggests that companies who invest in disruptive technologies can expect to see a 10% bump in revenues and may even improve their gross margins by over 21%. Yet, only 6% of CEOs report that they are satisfied with their innovation performance. 

WHAT ARE THE BARRIERS TO INNOVATION?

Understanding the barriers to innovation is crucial for addressing the innovation disconnect. Potential roadblocks include: 

While these concerns have merit, its estimated that 62% of companies plan to prioritize innovation, recognizing that the potential rewards are worth the risks. In doing so, it is important to approach the innovation disconnect with a strategic approach. 

How Do We Resolve the Innovation Disconnect?

Addressing the disconnect requires brands to adopt a culture of innovation. A 2022 McKinsey report estimated that companies who do so are 3.5 times more likely to outperform their counterparts who do not. Brands can begin by: 

Topperforming companies are ramping up their strategic partnerships to develop new products and expand their offerings, allowing them to innovate faster than would be possible without external support. In fact, nearly half of top economic performers initiated a new partnership in 2020-2021. 

Case Study: CELLIANT, the First Wellness Ingredient Brand

Wellness continues to be a top priority among consumers. The global wellness industry is predicted to reach $8.5 trillion by 2025. Brands seeking to capitalize on these trends can leverage partnerships with wellness innovators to offer products that do more for their customers, providing physiological benefits on top of basic function. 

CELLIANT® infrared technology can transform any textile product into a wellness product, and is a key ingredient in products from leading brands in industries spanning apparel, sports and outdoor, bedding, health and wellness, hospitality, transportation and more. CELLIANT offers brands science-backed, rigorously tested wellness technology that is adaptable and scalable to meet a range of product development needs. A brand partnership with CELLIANT can offset the need for research and development while empowering brands to re-invent their product hierarchies.  Below are a few ways that CELLIANT has helped partners grow and succeed: 

If you are interested in exploring innovation opportunities and want to learn if CELLIANT is a fit for your brand, fill out the form below to set up a meeting with a member of our team. 

GET IN TOUCH

SOURCES

SHARE THIS

𝕏

MORE LIKE THIS

STAY CONNECTED

The FDA determined products containing CELLIANT® are medical devices because they are intended to temporarily increase blood flow and local circulation at the site of application in healthy individuals.

The FDA has determined that CELLIANT® products are medical devices as defined in section 201(h) of the Federal Food, Drug and Cosmetic Act and are general wellness products.

The FDA has not approved or designated CELLIANT® products for any purpose and has not made any determination about, or endorsement of, its stated use or benefits.
As part of the 513(g) submission process, the FDA reviewed and commented on appropriate health and wellness claims for CELLIANT products.

CELLIANT® is designated as a Class 1 Medical Device in Australia, Canada, the European Union, Japan, New Zealand, the United Arab Emirates and the United Kingdom. CELLIANT® is cleared to market in China, India, Indonesia, Korea, Malaysia, Mexico, Peru, Philippines, Saudi Arabia, Singapore, South Africa, Taiwan, Thailand and Vietnam, with more countries and regions to follow.

For more information on the FDA classification of a medical device, visit the U.S. FDA site.

REQUEST INFORMATION